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1 
Abstract 
The purpose and aims of this qualitative descriptive study were to describe how past experiences 
with research (including communication, information, values and support) may contribute to 
research fatigue among youth and parents of youth with HIV, CF, and T1D.  Eighteen parents 
and youth were purposively recruited from outpatient subspecialty clinics at a major academic 
medical center.  They took part in qualitative interviews, completed a demographics form, and 
the Decisional Conflict Scale.  Youth participants also completed the Erikson Psychosocial Stage 
Inventory.  Two major themes emerged:  blurred lines and hope for the future.  Research fatigue 
was not found in this sample.  Results point to challenges with informed consent in settings 
where research and clinical care are integrated, and suggest that protective factors allow for 
continued participation without excess burden on youth and parents.  Strategies to minimize 
research fatigue and support engagement in research are offered.  
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Introduction and Specific Aims 
Clinical research is necessary to improve the care and treatment of individuals living with 
chronic health conditions (CHC).  The National Institutes of Health (1998) require that children 
under the age of 21 be included in all human subjects’ research.  This underscores the 
importance of including of youth in clinical research agendas for CHC.  HIV infection, cystic 
fibrosis (CF), and type 1 diabetes (T1D) are examples of CHC that have benefitted from 
pediatric-focused research funding by numerous private and governmental agencies (Cystic 
Fibrosis Foundation, 2014; National Institutes of Health, 2014; Type 1 Diabetes TrialNet, 2014) 
leading to significant advances in treatment and improved outcomes.  These conditions share 
common features:  the need for daily medications and frequent medical follow up, the potential 
for complications and reduced life expectancy, and the lack of available cure.  Youth living with 
these CHC are likely to have been approached about participation in clinical research and may be 
asked to engage again as the research agendas in these areas are progressive and include the 
efforts to find a functional cure for HIV (Deeks et al., 2012), the use of mutation-specific drug 
therapy in CF patients (Pettit, 2012), and the use of continuous loop technology in the 
management of T1D (Larson & Pinsker, 2013; Phillip et al., 2012).   
One challenge to enrollment is when eligible participants decline to take part.  Failing to 
meet target accrual in a clinical research study negatively impacts power, internal and external 
validity (Burns, 2009), and the ability of the study to address its primary endpoints (Schroen et 
al., 2012).  Enrollment refusal and attrition are high in studies of youth with chronic conditions, 
with rates of refusal averaging 37% and attrition 20-32% (Karlson & Rapoff, 2009).  Slow 
recruitment can lengthen the data collection period resulting in excess cost and premature closure 
of the study (Muth, Yu, Alston, & Ellenberg, 2001; Peters-Lawrence et al., 2012). 
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Studies examining factors that influence youth participants and their parents have focused 
on motivations to participate in clinical research (Broome & Richards, 2003; Tait, Voepel-Lewis, 
& Malviya, 2003; Wynn et al., 2010).  Reasons for declining research participation have been 
less thoroughly investigated; however children and adolescents are strongly influenced by 
relationships with adults, particularly their parents and research staff (Broome & Richards, 2003; 
Broome, Richards, & Hall, 2001). 
For HIV-infected youth, it has been hypothesized that participation burn-out from 
repeated research engagements may be to blame for declining research participation (Pagano-
Therrien, 2013).  Research fatigue and related concepts have been described in a number of 
fields (Bradburn, 1978; Clark, 2008; Finau, 2011; Helgesson, 2011; Kolch et al., 2010; Maar et 
al., 2011; Odland & Nieboer, 2012; Sharp, 1983; Shue, 2011; Ulrich, Wallen, Feister, & Grady, 
2005) but have not been explored in youth with CHC who have taken part in clinical research.  
Research fatigue is defined as apathy, indifference, or resistance to research (Clark, 2008).  
Because further advances in science will help improve the health and well being of youth with 
HIV, CF, and T1D, the goal is to promote engagement in research, and to decrease the burden of 
participation and the incidence of research fatigue among youth with these targeted CHC.   
The purpose of this qualitative descriptive study is to describe how past experiences with 
research may contribute to research fatigue among youth and parents of youth with HIV, CF, and 
T1D.  Components of the decisional conflict framework (O'Connor, 1995, 2010) will guide this 
study.  Youth and parents of youth with HIV, CF, and T1D who have previously participated in 
or declined participation in a clinical research study will be interviewed separately.  The specific 
aims of this study are to: 
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1.  Describe how communication and information about past clinical research 
participation informs decision-making about research participation among youth and parents of 
youth with chronic health conditions. 
2.  Describe how participant’s values influence decision-making about engagement in 
clinical research among youth and parents of youth with chronic health conditions. 
3.  Describe what types of support youth and parents of youth with chronic health 
conditions perceive to be important to decrease participation burden and research fatigue.   
4.  Describe potential strategies to optimize support for decision-making about 
participation and for reducing burden and fatigue among youth and parents of youth with CHC 
taking part in clinical research.  
The ability to engage these populations in research is critical to advance science and 
improve the health and well being of youth with CHC in general.  The long term goal is to 
improve the overall approach to clinical research through the development of interventions to 
engage youth and their parents without over burdening families by providing necessary support 
and facilitating informed, collaborative decision-making. 
Background and Significance 
 Factors Influencing Research Participation Among Youth 
Studies of motivators and barriers to the engagement of youth in research have focused 
primarily on factors that influence parental attitudes and decision-making (Barratt, Levickis, 
Naughton, Gerner, & Gibbons, 2013; Buscariollo et al., 2012; Caldwell, Butow, & Craig, 2003; 
Hoberman et al., 2013; Rothmier, Lasley, & Shapiro, 2003; Sammons, Atkinson, Choonara, & 
Stephenson, 2007; Tait et al., 2003; Tait, Voepel-Lewis, Siewert, & Malviya, 1998; van 
Stuijvenberg et al., 1998; Woolfall et al., 2013; Wynn et al., 2010).  Studies describing the 
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perspective of children and adolescents indicate that participation is highly influenced by 
relationships with adults, including parents and research staff (Broome & Richards, 2003; 
Broome et al., 2001).  Communication between a child and parent may directly influence the 
parental decision to consent (Tait et al., 2003) and parental decisions may be impacted by their 
child’s health status (Sammons et al., 2007), where parents with children who are acutely ill may 
be more likely to consent.   
Table 1 summarizes the motivations and barriers to participation in clinical research as 
described by parents, children, and adolescents in a variety of qualitative and quantitative 
studies, including randomized controlled trials (RCT).  The populations of youth under 
investigation in these studies represent a wide variety of pediatric conditions including, but not 
limited to:  asthma, type 1 diabetes, surgery, pneumonia, obesity, vesico-ureteral reflux, sickle 
cell disease, neurodevelopmental and sleep disorders, and steroid induced osteopenia.   
Table 1:  Factors influencing research participation 
Motivations, or reasons given by those who 
consent to participate 
Barriers, or reasons given by those who 
decline participation 
Parental perspective 
To contribute to science or medical 
knowledge (Rothmier et al., 2003; 
Sammons et al., 2007; van Stuijvenberg et 
al., 1998; Wynn et al., 2010) 
To benefit one’s child (Buscariollo et al., 
2012; Hoberman et al., 2013; Sammons et 
al., 2007; Tait et al., 2003; van 
Stuijvenberg et al., 1998; Woodgate & 
Edwards, 2010; Wynn et al., 2010) 
To gain more information (Caldwell et al., 
2003; Rothmier et al., 2003; Sammons et 
al., 2007; van Stuijvenberg et al., 1998) 
Desire closer monitoring or follow up 
(Caldwell et al., 2003; Hoberman et al., 
2013; Sammons et al., 2007; Wynn et al., 
2010) 
Physician or staff trust and/or encouragement 
(Buscariollo et al., 2012; Caldwell et al., 
Fear of randomization, unknown, negative 
experiences (Barratt et al., 2013; Caldwell 
et al., 2003; Hoberman et al., 2013; 
Sammons et al., 2007; Tait et al., 2003; 
Wynn et al., 2010) 
Uncertainty 
 Due to placebo (Tait et al., 2003; van 
Stuijvenberg et al., 1998)  
 Due to risks, side effects (Buscariollo et 
al., 2012; Caldwell et al., 2003; 
Sammons et al., 2007; Tait et al., 2003; 
van Stuijvenberg et al., 1998; Wynn et 
al., 2010) 
Distrust of research (Buscariollo et al., 2012; 
Tait et al., 2003; Wynn et al., 2010) 
Child as “guinea pig” (Buscariollo et al., 
2012; Caldwell et al., 2003; Tait et al., 
2003) 
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2003; Hoberman et al., 2013; Rothmier et 
al., 2003; Tait et al., 2003; Woodgate & 
Edwards, 2010; Woolfall et al., 2013) 
Study and consent understandable, favorable 
risk versus benefits, adequate time to 
decide (Buscariollo et al., 2012; Caldwell 
et al., 2003; Hoberman et al., 2013; Tait et 
al., 2003) 
Shared parental and youth perspectives 
To benefit others (Broome et al., 2001; 
Buscariollo et al., 2012; Caldwell et al., 
2003; Sammons et al., 2007; van 
Stuijvenberg et al., 1998; Wendler, 
Abdoler, Wiener, & Grady, 2012; 
Woodgate & Edwards, 2010; Woolfall et 
al., 2013) 
To access a new drug or treatment (Broome & 
Richards, 2003; Caldwell et al., 2003; 
Rothmier et al., 2003; Woolfall et al., 
2013; Wynn et al., 2010) 
Financial benefit, incentives (Broome & 
Richards, 2003; Caldwell et al., 2003; 
Rothmier et al., 2003) 
Invasive tests involving needles,(Sammons et 
al., 2007) extra bloodwork or diagnostic 
procedures (Broome & Richards, 2003; 
Wynn et al., 2010) 
Time commitment, convenience (Barratt et 
al., 2013; Broome & Richards, 2003; 
Buscariollo et al., 2012; Caldwell et al., 
2003; van Stuijvenberg et al., 1998; Wynn 
et al., 2010) 
 
Parents and youth agree to research participation when there is clarity about the potential 
benefits:  accessing a new drug or treatment; receiving more intensive follow up; accessing new 
information about the condition; or potential financial compensation (Broome & Richards, 2003; 
Caldwell et al., 2003; Hoberman et al., 2013; Rothmier et al., 2003; Sammons et al., 2007; van 
Stuijvenberg et al., 1998; Woolfall et al., 2013; Wynn et al., 2010).  Parents assess whether the 
benefits of a study outweigh potential risks, and the likelihood of participation is higher when 
parents perceive a study to be important (Tait et al., 2003) and low-risk (Hoberman et al., 2013; 
Tait et al., 2003).  Parents and youth are also motivated by altruism, specifically, a desire to help 
others with the same medical condition (Broome et al., 2001; Buscariollo et al., 2012; Caldwell 
et al., 2003; Sammons et al., 2007; van Stuijvenberg et al., 1998; Wendler et al., 2012; Woodgate 
& Edwards, 2010; Woolfall et al., 2013), or more broadly, to contribute to scientific or medical 
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knowledge (Rothmier et al., 2003; Sammons et al., 2007; van Stuijvenberg et al., 1998; Wynn et 
al., 2010).  This desire to help may be driven by a feeling of obligation on the part of parents 
(Caldwell et al., 2003; van Stuijvenberg et al., 1998).  
Trust and positive communication between research staff, parents, and patients can 
influence the decision to participate (Broome & Richards, 2003; Rothmier et al., 2003; Tait et al., 
1998; Woodgate & Edwards, 2010; Woolfall et al., 2013).  Encouragement and support from 
care providers are motivators.  Communication includes written information of study details, 
such as the understandability of the informed consent form.  Poor communication is a potential 
barrier to participation.  Putting pressure on families, by giving them insufficient time or space to 
consider the research, can lead to distrust of the researcher or the research process (Buscariollo et 
al., 2012; Tait et al., 2003; Wynn et al., 2010).   
Burden is a major barrier to clinical research participation and includes the invasiveness 
of study procedures.  Perceived burden varies based on the type and frequency of study 
evaluations, where procedures involving needles (e.g. blood tests and injections) were deemed 
particularly burdensome to families (Buscariollo et al., 2012; Caldwell et al., 2003; Sammons et 
al., 2007; Wynn et al., 2010).  Burden also refers to the inconvenience of participation, including 
factors such as time commitment, travel and transportation arrangements, and the need to miss 
work or school.  Fear and uncertainty of study safety and risk of side effects, both known and 
unknown, are barriers to participation.  Higher levels of parental uncertainty and anxiety are 
associated with refusal to participate (Hoberman et al., 2013; Sammons et al., 2007).  
Uncertainty is highest in studies that include placebos, randomization, and/or blinding 
(Tait et al., 2003; van Stuijvenberg et al., 1998).  Parents who have a greater understanding of 
research (Tait et al., 2003) and the principles of randomization and blinding (Hoberman et al., 
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2013) are more likely to consent for their child to participate.  Parents who decline participation 
for their child often fear their child being used as a guinea pig (Buscariollo et al., 2012; Caldwell 
et al., 2003; Tait et al., 1998).  
Respondent Burden and Research Fatigue 
Respondent burden, defined as the research subject’s perception of psychological, 
physical, or economic hardship associated with participation in research (Ulrich et al., 2005), can 
present a significant challenge to study enrollment and can negatively impact data quality.  
Interviews that require significant time and effort, involve the collection of sensitive information, 
or necessitate multiple sessions to complete add to burden (Bradburn, 1978; Sharp, 1983).  
Measurement scales that involve a large number of variables and are lengthy or time consuming 
are also burdensome (Strickland, 1996).  Minimizing the burden of study procedures is noted to 
be an important safeguard (Kolch et al., 2010) for children who are considered to be a vulnerable 
population requiring special protection as research subjects (National Institutes of Health, 1998).  
Research fatigue manifests as apathy, indifference, or resistance to research and arises 
from subjects who are unable to recognize changes as a result of previous research participation, 
or who become overwhelmed by practical issues related to repeated research participation, such 
as time, financial strain, or transportation (Clark, 2008).  Research fatigue has been documented 
among small, vulnerable, or under-represented groups (Finau, 2011; Maar et al., 2011; Odland & 
Nieboer, 2012).  Contributing factors include:  perceptions of helplessness and the research as 
overly investigator-driven; failure to consider the value of community input to ensure culturally 
and contextually relevant studies; perceptions that previous research is being duplicated or 
results are not being translated; utilized research methods do not engage the participants or are 
not preferred by a given population; lack of communication resulting in feelings that nothing has 
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changed or that no feedback was given to participants based on prior research findings (Finau, 
2011; Maar et al., 2011; Odland & Nieboer, 2012).  Avoidance of research fatigue is important 
for successful recruitment and retention to studies in populations that may have repeated 
opportunities for research participation.  Research fatigue has not been formally studied in 
children, but has been suspected in a small group of research-experienced HIV infected youth 
(Pagano-Therrien, 2013), but the proposed study will be the first to formally explore research 
fatigue in a population of youth who have participated in research for various chronic illnesses.   
Chronic Health Conditions in Youth 
Conditions such as asthma, which may only require episodic care, and obesity, which can 
be reversed with lifestyle interventions, are increasingly common, but are driven by social and 
ecological causes (Halfon & Newacheck, 2010) that place these conditions in a different 
category from HIV, CF, and T1D.  These conditions are similar in the need for daily medication, 
frequent medical appointments, and the potential for complications and reduced life expectancy.  
These three CHC are set apart from many others because there are currently no cures available.  
Each has the potential to be immediately life threatening, but with treatment, individuals can be 
stabilized, altering the clinical course from acute to chronic.  The advancement of care and 
treatment for youth with HIV, CF, and T1D can be directly attributed to clinical research.   
Current Research in HIV, CF, and T1D 
Several recent reports in the HIV literature have generated excitement at the prospect of 
achieving an HIV cure (Hutter et al., 2009; Hütter & Thiel, 2011; Persaud et al., 2013; Saez-
Cirion et al., 2013; Taylor, Wilkin, Shalev, & Hammer, 2013).  These reports highlight the 
importance of examining HIV reservoirs in working towards a functional or sterilizing HIV cure, 
and the potential role of perinatally HIV-infected youth as subjects of investigation.  Nursing 
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research on the aging perinatally infected population is ripe for investigating issues of self 
efficacy (Erlen, Cha, Kim, Caruthers, & Sereika, 2010) and related issues in the transition from 
pediatric to adult care (Pearlstein et al., 2013).  Improving medication adherence (Robbins et al., 
2013), HIV prevention (Fisher, Lee, & Boudreau, 2014), as well as management of depression 
and other mental health issues (Brawner, 2012) in youth with HIV also require further study. 
Although initially promising, gene therapy for treatment of CF has proven challenging 
and there are currently no ongoing human clinical trials involving gene therapy for CF (Hoffman 
& Ramsey, 2013).  However, improvement in quality of life remains a priority with current 
research focusing on the CF model, including impaired mucociliary clearance, airway 
obstruction, inflammation, and infection (Hoffman & Ramsey, 2013).  The first CF 
transmembrane regulator (CFTR) modulating drug (Ivacaftor [Kalydeco]) was recently approved 
to treat the G551D mutation which is present in 5% of individuals with CF (Hoffman & Ramsey, 
2013).  CFTR modulators improve pulmonary function, increase body weight, and decrease the 
number of pulmonary exacerbations, all of which contribute to improved quality of life (Davies 
et al., 2013; Pettit, 2012).  Research focusing on a similar drug to treat the more common CF 
mutation, F508del, represents a shift to personalized medicine, aiming to directly treat the 
underlying mutation based on an individual’s genotype (Pettit, 2012).  Nursing research to 
address medication adherence, physical activity, and nutrition (Bradley, Madge, Morton, 
Quittner, & Elborn, 2012) will also benefit overall quality of life.  Like youth with HIV, there is 
also much to be learned about self efficacy (Mickley, Burkhart, & Sigler, 2013) and the 
transition of care from pediatric to adult CF providers (Al-Yateem, 2012). 
Immune system modulation in individuals with T1D has been a focus of research over the 
past decade.  The Immune Tolerance Network (ITN), a multi-centered, NIH-funded group, has 
PAGANO-THERRIEN PROPOSAL  12 
been responsible for multiple clinical trials of immune modulating agents (Ehlers & Nepom, 
2012) including anti-CD20 monoclonal antibody (Rituximab) and anti-interleukin-1 beta 
monoclonal antibody (Gan, Albanese-O'Neill, & Haller, 2012), although the results of these 
trials have been mixed. Continuous glucose monitoring (Larson & Pinsker, 2013; Phillip et al., 
2012; Tansey et al., 2013) in youth with T1D is a newer technology that was recently approved 
for use in children and adolescents (Food and Drug Administration, 2014).  Adherence and 
quality of life (Mlynarczyk, 2013) are important areas of nursing research that will be important 
to re-examine in light of this new technology.  Nursing research on diabetes self management 
(Hanna et al., 2013) is critical as these youth also move towards transition to adult care.   
As research in these areas moves ahead, researchers must be cognizant of research fatigue 
and the burden placed on youth and their families from participation in multiple studies.  
Because every encounter with research can influence decisions about future engagement, it is 
vitally important to assess whether research fatigue may be present in these populations, and 
whether this phenomenon affects decision-making about research participation among youth and 
parents of youth with CHC. 
Conceptual Framework 
The decisional conflict framework has been used to guide decisions about treatment and 
may be adaptable for decision-making by youth and their parents about research participation.  
Youth with CHC and their parents or caregivers face decisions related to their heath care that 
may include deciding whether to take part in clinical research.  Decisional conflict is present 
when there is uncertainty about the course of action to take (O'Connor, 1995) or when opposing 
tendencies are present that interfere with decision-making (Janis & Mann, 1977).  Uncertainty in 
decision-making is highest when the decision involves risk, challenges personal values, results in 
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significant gains or losses, or when the potential implications of the decision are unclear 
(Keeney, 1982; O'Connor, 1997).  Decisional conflict manifests prior to decision-making (Janis, 
1959) and may be related to a lack of information about options, lack of experience with decision 
making, perceived external influence such as that of a health care provider or family member, 
and lack of an adequate support system (O'Connor, 1997).    
Literature suggests that research fatigue manifests primarily as apathy, indifference, or 
resistance to research (Clark, 2008).  The contributing factors usually involve practical issues 
like excessive burden or hardships of some kind that might be relieved with adequate supports.  
Other contributing issues relate to the perceived value of research, and communication of 
information between investigators and participants.   
This study aims to explore whether youth and parents of youth with CHC report features 
of research fatigue as factors that contribute to their uncertainty and decision-making conflict 
about clinical research participation.  An adapted decisional conflict framework will be used to 
explore the common factors that contribute to decision-making uncertainty and to research 
fatigue (Figure 1). 
 
Figure 1: Decisional Conflict framework applied to research decision-making and research fatigue. 
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Methods 
Design 
This study will use qualitative description (Sandelowski, 2000, 2010) to describe the 
experience of youth and parents of youth with CHC with clinical research participation, the 
factors that influence their decision-making, and whether research fatigue plays a role.  
Sample/Sampling 
Stratified purposive sampling will be used to recruit both youth and parents of youth with 
each of the targeted CHC (Table 2) who have previously made decisions about clinical research 
participation in order to obtain a rich description of their experiences.  Recruitment of parent-
child dyads was considered.  However, given that this study will recruit youth and parents of 
youth with past research experience, it was decided that dyad recruitment could result in bias if 
only the parent or youth agreed to participate while the other declined, or if the parent was not 
available or deceased, as may be the case with many HIV infected youth who would otherwise 
be eligible to take part in this study.  Dyad recruitment would likely result in a more 
homogeneous population of parents and youth who are very enthusiastic about and experienced 
with research.  Enrolling individual participants will allow for a description of the unique 
experiences of the intended heterogeneous population.  Disparate as well as concordant 
youth/parent decision-making processes will be described.  All study participants will be 
interviewed separately and analysis of youth and parents data will be conducted separately.  For 
the purpose of this study, a parent is defined as a natural or adoptive parent or legal guardian.  
Maximum variation sampling will ensure that participants vary in the number and types of 
studies for which they were approached or in which they participated.  Participants who have 
declined participation will also be included.   
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A target sample size of 30 participants falls within the recommended range for qualitative 
studies, which is anywhere from 10-50 participants, depending on the specific type of qualitative 
method being used (Sandelowski, 1995).  Because the sample will be heterogeneous, both in 
terms of the type of chronic health condition and prior research experience, the target sample size 
falls on the higher end of this acceptable range.  The final sample size will be determined by the 
number of participant interviews required to reach informational redundancy (Lincoln & Guba, 
1985), which will be achieved when no new ideas emerge from the interviews and the categories 
of ideas are fully explored (Creswell, 2013).  The final sample size will be determined during the 
conduct of the study in consultation with qualitative research mentors.    
Table 2:  Intended sample 
N=30 
HIV Cystic 
Fibrosis 
Type 1 
Diabetes 
Youth n=5 n=5 n=5 
Related or un-related parents/legal guardians of youth n=5 n=5 n=5 
 
Inclusion and Exclusion Criteria 
Inclusion criteria for youth participants include:  diagnosed with HIV, CF, or T1DM; 
current age 13-21; prior participation or invitation to participate in at least one clinical research 
study at any point through age 21; English speaking.  The upper age limit of 21 was chosen for 
this study to coincide with the age at which transition from pediatric to adult health care settings 
is typically accomplished (American Academy of Pediatrics, American Academy of Family 
Physicians, American College of Physicians, & Transitions Clinical Report Authoring Group, 
2011).  Parental inclusion criteria include:  parent or legal guardian of a youth with HIV, CF, or 
T1D who participated or was invited to participate in at least one clinical research study through 
age 21 (youth does not need to participate in this study); English speaking, took primary 
responsibility for providing consent for past clinical research participation.  All participants must 
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demonstrate willingness to participate in the interview by reviewing and signing the informed 
consent or assent documents.   
Cognitive impairment that would prevent a participant from responding meaningfully to 
interview questions will be an exclusion criterion and determined in consultation with the 
referring care providers.  Therefore, clinical care providers from the HIV, CF, and T1D clinics 
will be asked to carefully consider referring candidates demonstrating dementia, psychosis, 
abnormal behaviors, confusion, forgetfulness, or difficulty communicating (Jeste et al., 2003). 
Individuals with mild cognitive impairment will not be excluded.  However, candidates 
must be able to provide their own consent or assent by demonstrating adequate capacity for 
decision-making (University of California San Francisco, 2010).  Decision-making capacity is 
the ability to make a meaningful decision about participation, including the ability to:  1) 
understand the study’s purpose, procedures, risks, and benefits; 2) appreciate the significance of 
the study and implications of the risks and benefits to the individual; and 3) engage in reasoning 
about the risks and benefits of participation (Jeste et al., 2003).  For this minimal-risk study, 
understanding of these elements of informed consent will be evaluated through an Evaluation to 
Sign Consent (ESC) (Appendix I) (DeRenzo, Conley, & Love, 1998; Sturman, 2005).  The 
principle investigator (PI), a nurse with 10 years of experience, will assess each candidate’s 
alertness and ability to communicate.  Candidates scoring 12 out of 12 possible points will be 
permitted to provide their own consent or assent to participate; all others will be excluded. 
Setting 
The setting for this study will be the outpatient subspecialty clinics, specifically, the 
pediatric HIV, pulmonary, and endocrinology clinics at a major academic medical center.  Five 
youth and five parents of youth will be recruited from each of the clinics for participation.  The 
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pediatric HIV clinic currently serves 38 infected youth.  Parents or guardians accompany a 
majority of youth to clinical visits and will be easily accessible for recruitment.  The pediatric 
HIV clinic has been involved in clinical trials, including phase I, II, and II drug studies, long 
term follow up, pharmacokinetic, and vaccine studies, for over 20 years.  At any given time, as 
many as ten or more studies have been ongoing.  The number of studies has decreased 
significantly in the past year; however, most patients have been involved in at least one, and as 
many as 16 studies over the course of their lives.  The diabetes clinic serves 571 children, and 
approximately 60 new youth with T1D enter the clinic each year.  The clinic is active in clinical 
trials of new drugs, behavioral intervention studies, and T1D screening studies.  On average, 
there are 5 studies ongoing at a given time.  The CF clinic currently serves 96 pediatric patients.  
Approximately 7 studies are currently being conducted, including phase II and III drug studies, 
and long-term observational and prospective outcomes.   
Procedures 
Thirty participants will be recruited purposively from the Pediatric HIV, CF, and T1D 
clinics.  Clinical care providers and study coordinators based in these clinics will assist with 
recruitment by distributing a flyer detailing the study.  This document will emphasize the 
importance of understanding the reasons why individuals have declined past clinical research 
studies and that their input will allow researchers to learn how make studies less burdensome and 
support potential participants in their decision-making.  Individuals meeting inclusion criteria 
will give permission to be contacted by the PI by phone to further discuss details of the study.  
Participants will then be scheduled for the study visit, where informed consent and assent will be 
obtained prior to individual interviews and completion of a demographics form and three 
instruments.  
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Data Collection 
Interviews will be conducted by this PI during face-to-face, audio-recorded, individual 
interviews using a semi-structured interview guide (Appendix II).  Youth and parents will be 
interviewed separately in order to describe their unique perspectives on research participation.  
Interviews will take place in a private conference room or office at the medical center at the 
convenience of the participant.  Field notes will be written immediately following each interview 
to document what was done and to summarize the interviewers’ observations and reflections.  
The interviews are anticipated to last approximately one hour.  Interviews will be audio recorded 
and then professionally transcribed.  In addition to interviews, participants will be asked to 
complete a demographics form (Appendix III).  To triangulate interview data, the Decisional 
Conflict Scale (DCS) and the Pediatric Research Participation Questionnaire (PRPQ) will be 
administered prior to the interview (Appendix III).  Completion of these instruments will 
contribute to this study’s trustworthiness.   
The decisional conflict scale. 
The DCS is a 16-item, 5 category response scale measuring personal perceptions of 
uncertainty, modifiable factors contributing to uncertainty, and effective decision-making.  The 
DCS will be preceded by a comment asking participants to complete the DCS considering their 
past experiences with decision-making about a research study.  Internal consistency (Cronbach’s 
Alpha) for the scale ranges from 0.78 to 0.92 (O'Connor, 1995).  Validation studies report less 
than 1% missing responses, contributing to face validity (O'Connor, 1995).  In evaluating 
construct validity, statistically significant (p<0.0002) differences were found between individuals 
with high and low DCS scores, supporting the scale’s validity (O'Connor, 1995).  Divergent 
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validity has also been assessed, with a weak but statistically significant inverse correlation (r=-
0.16; p<0.05) found between high DCS scores and low levels of knowledge (O'Connor, 1995). 
The pediatric research participation questionnaire. 
The PRPQ is a measure designed to aid in understanding decision-making about clinical 
trials participation among pediatric patients with CHC (Barakat et al., 2013).  This questionnaire 
will be used to capture motivators and barriers to participating in clinical research for their (or 
their child’s) CHC.  Three versions have been newly developed:  a 12 item, yes/no response 
questionnaire for children ages 8-15 years; a 21 item, agree/disagree questionnaire for 
adolescents and young adults ages 16-39 years old; and a 21 item, agree/disagree questionnaire 
for caregivers.  Internal consistency coefficients for these recently developed scales have not yet 
been reported.  This scale will be utilized only if Cronbach’s alphas become available and are 
>0.7.   
Data Management 
Electronic data will be stored on a secured research drive on the University server that is 
backed up nightly.  Access to this drive will be limited to the PI and dissertation chairperson.  
Every transcript will be reviewed against the original audio recording to ensure accuracy of 
transcription.  NVivo (version 10) software will be utilized to prepare interview summaries.  
SPSS (version 22) will be used to manage demographic information and quantitative data 
generated from the DCS and PRPQ. To minimize missing data, the paper instruments will be 
reviewed for completion prior to the participant leaving the interview session.  Double entry of 
data will be performed to ensure accuracy.  
Data Analysis 
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Qualitative Content Analysis (Miles, Huberman, & Saldana, 2013) will be used to 
analyze the interview data.  Transcripts will be read and summarized as the study progresses.  
Data reduction will be achieved by reviewing one section of data at a time.  Transcripts will be 
examined for similarities and analysis will be done across cases.  NVivo software will then be 
utilized to accomplish coding.  Data will be placed in code folders, documenting coding rationale 
in the field notes.  Rebuilding of data will be accomplished through the development of 
categories by looking for links between codes.  The interview guide will be revised, as needed, 
during the conduct of the interviews as the transcripts are analyzed across cases.  To ensure 
maximum variation across participants, purposive sampling will take place as the study unfolds 
to attempt to vary the number and type of studies participants.  Field notes will document the 
analysis process. 
Analysis will include within and across-participant comparisons of DCS scores and 
interview responses.  In particular, the interview transcripts will be examined for participants 
with high DCS scores, representing a high level of decisional conflict, for common themes.  
Similarly, thematic analysis of transcripts will be done for participants with low DCS scores, 
which represents a low level of decisional conflict.  The themes generated from high and low 
scoring participants will then be compared.  The PRPQ yields dichotomous (yes/no, or 
agree/disagree) responses to understand the perceived benefits and barriers to research 
participation.  Within-participant PRPQ responses will be examined and used to validate 
qualitative interview responses to questions about benefits and barriers to participation.  Across-
participant PRPQ responses will be analyzed against the qualitative interview themes.  Thematic 
analysis of qualitative data will also take place across-participants with similar PRPQ responses 
with high and low DCS score.   
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If elements of research fatigue emerge from the qualitative data, further analysis will take 
place to compare within-participant descriptions of research fatigue to DCS scores and PRPQ 
responses to make an assessment as to the utility of these scales in future studies on research 
fatigue.  However, the intended sample size is too small to draw statistical conclusions. 
To ensure trustworthiness, the following techniques will be employed:  peer debriefing, 
member checks, purposive sampling, rich description, triangulation, reflexive journaling, field 
notes, and an audit trail (Lincoln, 1985).  Through regular, modified peer debriefing meetings, 
the PI will benefit from the insight of dissertation committee members, who are experts in 
conducting qualitative research.  Interview proceedings, audio tapes, transcripts, and preliminary 
data findings will be discussed.  At least 2 youth and 2 parents who are willing to take part in 
member checks will be contacted to review de-identified transcripts and the PI’s preliminary data 
interpretations to ensure their ideas were accurately captured.  Transferability of findings from 
this study will be enhanced through purposive sampling to achieve a rich description of the 
participant’s experiences with research. 
The PI will take part in reflective journaling throughout the study to record personal 
feelings and reflections, and all study activities and interview observations will be recorded in 
field notes.  These documents will be considered part of the audit trail and will be reviewed in 
the peer debriefing meetings and at the request of the dissertation committee members.  
Human Subjects Involvement 
Participants will be male and female youth or parents of youth with HIV infection, CF, or 
T1D recruited from the pediatric clinics at UMMC-CMC.  To gain the perspective of children 
who have been involved in clinical research, inclusion of this vulnerable population is necessary 
in the effort to improve research procedures in the future that minimize burden and support 
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informed decision-making among children and families.  Pregnant women may be involved in 
this study if they are a youth with HIV, CF, or T1D, or if they are already the parent of a youth 
with HIV, CF, or T1D.  Pregnant women will not be excluded because this study does not pose 
harm or seek to collect information about the pregnancy or the fetus.  Prisoners and 
institutionalized individuals will be excluded from participation.  Youth participants will be 
between 13 and 21 years of age, and their ability to contribute meaningfully to the interview will 
be determined in consultation with their clinical care providers who will assess referred 
participants for severe cognitive deficits including dementia, psychosis, abnormal behaviors, 
confusion, forgetfulness, or difficulty communicating (Jeste et al., 2003).  Parents or legal 
guardians will be at least 18 years of age.  Subjects will reflect the socio-demographic 
composition of the clinics, which is variable across these three populations (Table 3).  Ethnicity 
and gender will not be used as criteria in determining eligibility.  Recruited participants will be 
asked to take part in a single interview and data collection session.  A $25 gift card to a local 
retail store will be provided to participants as a gesture of gratitude for their participation.  
Member checks to validate study data will be conducted with at least 2 youth and 2 parents who 
will be selected based on their willingness to be re-contacted and their potential to provide 
meaningful review of the study data.  An additional $25 gift card will be provided to participants 
who take part in member-checks.   
 
Table 3:  Racial and 
ethnic composition of 
available clinical 
populations  
Caucasian Hispanic Black Asian Other 
race 
Not 
reported/unknown 
HIV 24% 50% 21% 5% 0% 0% 
CF 88% 2% 0% 0% 3% 7% 
T1D 84% 2% 3% 1% 6% 4% 
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Potential Risks and Protections 
 There are no anticipated physical risks to participants.  However, there is the rare chance 
that participants may become upset when talking about their/their child’s chronic health 
condition or their past research experience.  This psychological risk will be included in the 
informed consent and discussed with participants in advance.  Before participating in research 
interviews, participants will be assured of their confidentiality and will be reminded that they 
have the right to terminate the interview or decline to answer specific questions, or terminate 
their participation at any point in the research process.   
The PI has extensive experience recruiting and interviewing children and parents in 
highly complex clinical trials, and is sensitive to the emotions that can emerge during study 
visits.  If at any time during the interview or data collection procedures a participant become too 
physically or emotionally tired or upset, they will be reminded that they have the option to stop 
the interview or data collection.  The PI will attempt to comfort the participant and provide any 
explanations that would be helpful.  If a child becomes upset, the parent will be notified, along 
with members of the clinical care team so that arrangements can be made for appropriate follow 
up with a mental health provider as needed.  If a parent becomes upset, the child’s clinical care 
team will also be notified so that support staff (i.e. licensed social worker) can be engaged as 
needed.  Participants exhibiting extreme distress will be escorted to Emergency Mental Health 
Services at the Emergency Department at UMMC, which serves children and adults. 
There is no anticipated financial risk, as the PI will work with participants to schedule 
interviews at a time when participants will not miss work.  There is always the potential for a 
loss of confidentiality when study instruments and data forms are completed, but every 
precaution will be taken to ensure that all data are kept strictly confidential.  Participant names 
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will not be used during the audio-recorded interviews.  Only the PI will have access to 
identifiable data (a list that links the study ID with participant names), which will be stored in a 
locked file cabinet in the PI’s locked office.  Personal identifiers will be stripped from the data 
and kept separately in a locked file available only to the PI.  All information provided by 
participants will be referenced to unique participant ID numbers and will be kept in a locked file 
cabinet.  The participants ID numbers could be connected to the participant’s names only 
through a single master file, accessible only to the PI.  Passwords and protection codes will be 
used to protect data files against inadvertent changes or unauthorized access.  All data files will 
be backed up nightly.  Documentation of the data management procedures will be carefully 
maintained.  Results will never be reported in a personally identifiable matter; only grouped or 
de-identified data will be presented in publications or presentations.  The usual standards for 
medical confidentiality will be observed.   
As a vulnerable population, the protection of children in this research study will be 
ensured by obtaining informed consent from one of the child’s parents or guardians.  Consent of 
only one parent or guardian will be required as this study is considered to present no greater than 
minimal risk.  Children will have the opportunity to affirm their agreement to the study by 
providing their assent.  Children whose parent/guardian provides informed consent, but who do 
not themselves provide assent will not be included in the study.   
Recruitment and Informed Consent 
Participants will be recruited from the UMMC Children’s Medical Center outpatient 
pediatric HIV, pulmonary and endocrinology clinics.  Prior to recruitment, an informational 
meeting at each outpatient clinic will be conducted to explain the study in detail to clinical care 
providers including physicians, nurse practitioners, and clinic nurses, as well as clinic-based 
PAGANO-THERRIEN PROPOSAL  25 
study coordinators.  Study coordinators in the HIV, CF, and T1D clinics will be crucial to the 
recruitment process.  The PI will request lists of active and inactive studies involving participants 
in these three clinics from the IRB and will then work with the study coordinators and principle 
investigators to identify potential participants who are developmentally capable to contribute 
meaningfully to the interview.  Study coordinators, or clinical care providers will be asked to 
provide an informational fact sheet explaining the study and a permission-to-contact form to 
potential participants as they attend clinic visits or by mail if there is no clinical visit scheduled 
during the data collection time period.  They will ask interested patients and parents to complete 
the permission-to-contact form.  This form will be approved by the UMMS IRB and will request 
that interested patients or parents provide basic contact information (name, phone number, and/or 
email address) and the most convenient day and time to have a discussion by phone.  The PI will 
contact all interested patients and parents by telephone to discuss the study in more detail.  
Potential participants will be given the PI’s phone number in the event they prefer to call rather 
than be contacted.  Patients and parents who remain interested in participating after learning 
details about the study will be scheduled for the study visit at a convenient time, and will have 
the option to receive a copy of the Informed Consent Form (ICF) by mail in advance of the visit. 
Prior to any data collection on the day of the study visit, the PI will meet with the study 
candidate and parent, if appropriate, in a private room to conduct the informed consent and/or 
assent processes.  It is anticipated that this will take approximately one-half hour.  Given the 
diversity of literacy rates in this population, the PI will then explain the ICF and assent form 
(AF) to every candidate/parent, reading the forms aloud for those who indicate that preference, 
and engaging in discussion about the content to ensure comprehension.  The participant/parent 
and minor participant aged 16 or 17 will be asked to read the ICF in full, or carefully consider 
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the contents read to them.  Minor participants aged 13-15 will be asked to read the AF in full, or 
carefully consider the contents read to them.  The PI will provide the candidate/parent with paper 
and pen to record any questions that arise as the ICF and AF are read or considered.  The PI will 
explain that participation in the study is voluntary and that their participation or lack of 
participation will not influence their/their child’s medical care.  The candidate/parent will be 
reminded that they can leave the study at any time and for any reason.  The PI will exit the room 
allowing the candidate/parent to review and consider the ICF and/or AF without feeling rushed 
or pressured.  The candidate/parent will indicate readiness to proceed with the informed consent 
and/or assent process by opening the door to the private room.  The PI will then answer any 
remaining questions.  Before the ICF and AF are signed, the ESC will be used to document the 
participant’s knowledge of the contents of the ICF.  Participants must score 12 out of 12 possible 
points to ensure adequate cognitive capacity to sign his/her own informed consent or assent. 
Informed consent will be provided by participants 18 years of age and older.  Informed 
consent for minor participants, defined for this study as a participant between the ages of 13 and 
17, will be provided by one parent or legal guardian of the minor participant.  Minor participants 
aged 13-15 will provide their assent to participate and will complete the assent form (AF).  
Minor participants aged 16 and 17 will indicate their consent, along with a parent or guardian, by 
co-signing the ICF, which is a standard procedural requirement of the University IRB.  
Potential participants/parents agreeing to participate will be asked by the PI to sign the 
IRB-approved written ICF and/or AF.  Consent and/or assent will only be obtained from each 
participant/parent after he/she acknowledges an understanding of the study and expresses a 
willingness to participate, and after the ESC is completed and passed.  The ICF will address the 
purpose of the study, study procedures, risks, confidentiality of materials, right to withdraw from 
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the study at any time, and the names of study contacts (i.e., the PI and IRB) in case of any 
concerns or questions.  The assent will address, in simpler terms, the same components as the 
ICF.  Two copies of the ICF, and AF if appropriate, will be signed by the participant/parent, of 
which one copy will be retained by the PI and the other given to the participant/parent.   
If at any point the participant/parent decides not to take part in the study, they will be 
asked to allow documentation of their reason for refusal.  This includes youth under 18 years of 
age who are willing to provide assent, but whose parents or guardians decline to give consent.  
Permission to collect basic de-identified demographic information (age, gender, race, ethnicity, 
highest level of education, marital status, and employment status for all participants and youth of 
parent participants; number of years since youth’s diagnosis; number and type of prior research 
studies participated in) will be requested.  There will also be a free text area for the participant or 
parent/guardian to describe in more detail the reason for refusal.   
Potential Benefits 
 There may be no direct benefit to individual subjects in this study.  However, participants 
could derive benefit from being able to express their feelings about their/their child’s past 
research experiences.  Further, information gained from this study could benefit future 
participants with chronic illness by allowing the PI to learn how to better approach parents and 
youth, and support their decision-making about research studies.  Participation in this study 
presents no greater than minimal risk.  It is reasonable to suggest that the potential benefits 
outweigh the minimal risk posed by this study. 
Potential Challenges 
There are three main challenges associated with this study.  It may be difficult to recruit 
participants who have already participated in multiple studies or previously refused research 
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participation.  To manage this challenge and promote recruitment of previous decliners, potential 
participants will be reminded that this study is different from other clinical studies; it is low risk 
and the time commitment is minimal.  Every attempt has been made to keep the research burden 
low by being flexible in scheduling study visits, limiting the number of questionnaires, and 
requesting only one interview session.  Participants will be reminded that data obtained in this 
study may be helpful in the future to improve the approach to engaging youth and parents in 
clinical research while minimizing burden and research fatigue.  Data about prior research 
participation refusal will be collected as a part of this study.  This data will be considered in the 
analysis of interview data, and will be reported in the results.   
A second potential challenge is that youth recruited for this study represent two different 
developmental levels.  According to Erikson, the goal of adolescence is to explore independence 
and work to develop a sense of self (identity versus role confusion); the focus of young adults is 
on exploring personal relationships and making commitments (intimacy versus isolation) 
(Erikson, 1950).  The identity and intimacy subscales of the Erikson Psychosocial Inventory 
Scale (EPSI) (Appendix III) will be used to classify youth participants by developmental level.  
Each subscale contains 12 randomly ordered items, half of which reflect successful resolution of 
the crisis associated with that developmental stage, and the other half unsuccessful resolution.  
The Likert responses range from 1-hardly ever true to 5-almost always true.  The scale is 
suitable for participants 13 years of age and older.  Alpha reliability coefficients from two test 
samples range from 0.71-0.78 for the identity subscale and 0.63-0.73 for the intimacy subscale 
(Rosenthal, Gurney, & Moore, 1981).  Analysis of data for youth participants will be undertaken 
with consideration for the developmental stages.  Between-subject comparisons will only be 
made between participants of similar age and developmental level. 
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Third, there is potential for recruitment bias as assenting youth under 18 years of age will 
not be permitted to participate without parental consent.  All participants who decline will be 
asked for permission to be added to a recruitment log.  This log will include basic demographic 
information and a free-text area to describe the reason for refusal.  Brief analysis of eligible 
participants who did not enroll will be described in the study results. 
Potential Contributions 
Knowledge gained from this proposed qualitative descriptive study has the potential to 
greatly improve how youth with CHC, a vulnerable population, are approached to engage in 
clinical research.  Advances in scientific and nursing knowledge to improve the health and well-
being of youth with CHC depend on the ability to recruit and retain participants in clinical 
research studies, which can be challenging when participants are faced with repeated requests.  
The perception of burden can be a significant barrier to research participation and this study will 
elucidate factors affecting that decision.   
The qualitative data collected during this study will set the stage for a research trajectory 
that will include:  (a) development of a scale to measure research fatigue; and (b) intervention 
studies to evaluate how to best engage youth with CHC and their parents in clinical research 
using innovative strategies to minimize burden and prevent research fatigue by providing 
adequate support and facilitating informed decision-making. 
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Name:  ________________________________________ 
 
Date of birth: ___________________________________       Score 
 
 
1) Is the patient alert and able to communicate with the evaluator?  ___ Yes (=2) ___ No (=0)  _____ 
 
2) Ask the participant to name two (2) potential benefits of participating in the study.   
0=not able to list potential benefits, 1=able to list one benefit, 2=able to list two benefits _____ 
  
 
 
 
3) Ask the participant to name two (2) potential risks incurred as a result of participating in the study.   
0=not able to list potential risks, 1=able to list one risk, 2=able to list two risks   _____ 
  
 
 
4) Ask the participant to name two (2) things that will be expected of him/her in terms of patient cooperation 
during in the study. 
0=not able to list expectations, 1=able to list one expectation, 2=able to list two expectations _____ 
 
 
 
5) Ask the participant to explain what he/she would do if he/she decided that they no longer wish to participate 
in the study.   
0=doesn’t know, 1=answers but not appropriate response, 2=talk to PI or clinical provider _____ 
 
 
 
6) Ask the patient to explain what he/she would do if he/she is experiencing distress or discomfort. 
0=doesn’t know, 1=answers but not appropriate response, 2= talk to PI or clinical provider _____ 
 
 
             
Total score _____ 
 
I hereby certify that the above participant is alert, able to communicate and able to give acceptable answers to 
items 2, 3, 4, 5, and 6 above. 
 
 
 
 
Evaluator        Date
Appendix I:  EVALUATION TO SIGN CONSENT (OR ASSENT) FORM (ESC) 
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Appendix II:  Interview Guide 
For youth participants 
Question Probes Conceptual 
Areas 
1. Can you tell me a little bit 
about your experiences when 
you have participated in a 
research study (or studies)?  
 
{Start here for those who have 
participated in a study in the 
past.} 
a. How many studies have you 
participated in? 
b. What kinds of studies were they? 
c. What were these studies like for you? 
d. How prepared were you for all of the 
requirements involved in the study? 
e. Did you have enough information 
about the study before you started it?  If 
not, what information would have been 
helpful to know? 
f. Do you remember how you first learned 
about the study and what you and your 
parent(s) talked about? 
g. What was the consent process like for 
you? 
h. Who supported you through this 
study?  
i. Did you have enough support or could 
you have used more support? 
j. What type of support did you find most 
helpful?  What types of support would be 
helpful in the future? 
k. Did you ever get information about the 
results of any research studies you were 
in?  Would that information help you to 
decide if you were invited to do another 
research study? 
General 
experience with 
research 
  
Informed consent 
 
 
 
 
 
 
 
 
Support 
 
 
 
 
 
Communication of 
information 
2. Can you talk a little bit about 
how you made the decision to 
participate (or not participate) in 
a research study? 
 
{Start here for those who have 
never participated in a study.} 
a. How did you make the decision? 
b. How much was your parent(s) involved 
in the decision-making process? 
c. Was anyone else involved in helping 
you make the decision? 
d. Did you experience any conflict with 
others or in your own mind about 
whether to participate in the study or not? 
e. What were some of the things that 
motivated you to participate (or not)? 
f. What were some of the barriers that 
you experienced when trying to decide 
whether to participate or not? 
g. How certain where you that this study 
was the right (not right) thing for you to 
do? 
Decision-making 
 
Support 
 
 
Uncertainty 
 
 
General 
motivators to 
participation 
General barriers 
to participation 
 
Values clarity (of 
research/youth) 
3.  Can you talk about how 
interested you are now in 
participating in future studies? 
a. Have you ever felt “tired” of being 
approached to be in these studies?  
Why? 
Research fatigue  
 
Values clarity (of 
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b. How important is participating in 
research to you personally? 
research) 
4. If you could teach the 
doctors and nurses who run 
these studies the best way to 
approach young people, like 
yourself, about research – what 
would you tell them? 
a. What are the things they should or 
should not do? 
b. How important is it that the research 
staff listens to your suggestions about 
research? 
 
Strategies for 
improving how we 
approach youth 
about research 
studies 
Values clarity (of 
youth) 
5. Is there anything else that 
you would like to add? 
  
 
For parents/guardians 
Question Probes Conceptual 
Areas 
1. Can you tell me a little bit 
about your experiences of 
having your child participate in 
a research study (or studies)?  
 
{Start here for those who have 
participated in a study in the 
past.} 
a. How many studies has s/he 
participated in? 
b. What kinds of studies were they? 
c. What were these studies like for you? 
d. How prepared were you, as a parent, 
for all of the requirements involved in the 
study? 
e. Did you have enough information 
about the study before s/he started it?  If 
not, what information would have been 
helpful to know? 
f. Do you remember how you first learned 
about the study and what you and your 
child talked about? 
g. What was the consent process like for 
you and your child? 
h. Who supported you and your child 
through this study?   
i. Did you have enough support or could 
you have used more support? 
j. What type of support did you find most 
helpful?  What types of support would be 
helpful if your child participates in the 
future? 
k. Did you ever get information about the 
results of any research studies your child 
took part in?  Would that information help 
you to decide if your child was invited to 
do another study? 
General 
experience with 
research 
  
Informed consent 
 
 
 
 
 
 
 
 
 
Support 
 
 
 
 
 
 
Communication of 
information  
2. Can you talk a little bit about 
how you made the decision to 
allow your child to participate 
(or not participate) in a 
research study? 
 
a. How did you make the decision to 
allow your child to participate? 
b. How much was your child involved in 
the decision-making process? 
c. Were any other people involved in 
helping you and your child make the 
Decision-making 
 
 
 
Support 
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{Start here for those who have 
never participated in a study.} 
decision? 
d. Did you experience any conflict with 
others or in your own mind about 
whether to let your child participate in the 
study or not? 
e. What were some of the things that 
motivated you to allow your child to 
participate (or not)? 
f. What were some of the barriers that 
you experienced when trying to decide 
whether to allow your child to participate 
or not? 
g. How certain where you that this study 
was the right (not right) thing for your 
child to do? 
Uncertainty 
 
 
General 
motivators to 
participation 
General barriers 
to participation 
 
Values clarity (of 
research/parent) 
3.  Can you talk about how 
interested you are now in 
allowing your child to 
participate in future studies? 
a. Have you ever felt “tired” of your child 
being approached to be in these studies?  
Why? 
b. How important is it to you for your child 
to participate in research? 
Research fatigue  
 
Values clarity (of 
research) 
4. If you could teach the 
doctors, nurses, and research 
staff the best way to approach 
young people about research – 
what would you tell them? 
a. What are the things they should or 
should not do? 
b. How important is it that the research 
staff listens to your suggestions about 
research? 
 
Strategies for 
improving how we 
approach youth 
about research 
studies 
Values clarity (of 
parent) 
5. Is there anything else that 
you would like to add? 
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Appendix III:  Data Collection Instruments 
Demographics 
Date of visit: ______________________ Participant ID #: __________________  
Age:  ________      Participant Status:  
Diagnosis:       _____ Youth  
_____ HIV       _____ Parent/legal guardian 
_____ CF       Year of youth diagnosis: ________ 
_____ T1D        
Gender:        Race: 
____ female       _____ Caucasian 
____ male       _____ Asian 
Ethnicity: _____ Black of African American 
_____ Hispanic or Latino     _____ American Indian 
_____ Not Hispanic or Latino     _____ Other 
_____ Unknown or not reported     If other, please list: _______ 
Level of Education:      Marital Status: 
_____ Some High School     _____ Single 
_____ High School diploma or GED    _____ Married 
_____ Some college      _____ Unmarried partners 
_____ Associates degree     _____ Divorced 
_____ Bachelors degree     _____ Separated 
_____ Masters degree     _____ Widowed 
_____ PhD or post-doctorate      
Employment Status:      Occupation (please list):  
_____ Full time      _____________________________ 
_____ Part time 
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_____ Unemployed 
_____ Retired 
_____ Student 
How many studies have you (your child) been invited to participate in since the time of 
diagnosis?  _______________ 
How many studies have you (your child) declined to take part in?  ________ 
 What types of studies were these?  __________________________________________ 
How many studies have you (your child) agreed to take part in?  ________ 
 What types of studies were these?  __________________________________________ 
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Traditional Decisional Conflict Scale (DCS)   Participant ID #: __________ 
Directions:  Please think back to the last time you were (your child was) invited to participate in 
a research study.  Please answer the following questions as you think about all the options you 
considered and how you made the decision to participate or decline. 
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Research Participation Questionnaire – Child (8-15 years old)  Participant ID #: ________  
  
Directions: While you go to the doctor or hospital to make you feel better, “research” asks you to 
participate in certain activities in order to learn things that will hopefully help others.   
Please check YES or NO to answer these questions.  We want to know what you think about 
medical (e.g., taking medicine, getting blood drawn) and psychosocial (e.g., thoughts and 
feelings about illness, coping with illness) research studies; there are no right or wrong answers.  
 
 Yes No 
1. I would do research if it was to learn more about my illness. 
 
  
2. Doing a research study will cause me more problems like having to 
take more pills, getting poked, and answering upsetting questions. 
  
3. I do research because my doctors and nurses take good care of me.  
 
  
4. Doing research gives my family and me a chance to help.  
 
  
5. I am willing to do research when I know exactly what I will be asked to 
do. 
  
6. Research will help my illness get better.  
 
  
7. I participate in research when my parent tells me to do it. 
 
  
8. The hospital has people to review studies to make sure they are safe.  
 
  
9. I don’t like doing research because I spend too much time at the 
hospital/clinic already. 
  
10. More people would do research if they got gift cards or gifts.  
 
  
11. Researchers sometimes hide facts from the people who do the 
studies. 
  
12. These people want me to be in research:  
12a. My healthcare team(doctor, nurse and social worker)  
  
12b. My family  
 
  
12c. My friends  
 
  
12d. My religious leader 
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Research Participation Questionnaire – AYA (16-39 years old)  Participant # _______  
 
Directions: While the goal of going to the doctor or hospital is to get care that is meant to benefit 
the patient and his/her family, “research” asks patients and families to participate in certain 
activities in order to learn things that will hopefully help future patients and families.   
Please check AGREE or DISAGREE to reflect your agreement or disagreement with each of the 
following statements.  We are interested in YOUR opinion about medical (e.g., taking 
medication, blood samples drawn) and psychosocial (e.g., thoughts and feelings about illness, 
coping with illness) research studies; there are no right or wrong answers.  
 
 Agree Disagree 
1. I would participate in research that helps me directly if:  
 1a. It gives me more contact with the healthcare team. 
  
1b. I learn more about my illness.  
 
  
1c. I get tests/medicine and equipment that my insurance won’t cover.  
 
  
1d. I get tests/medicine and equipment that are not available to the 
public. 
  
2. Research will cause me discomfort in the following ways:  
 2a. Require increased procedures. 
  
2b. Ask personal or upsetting questions.  
 
  
3. I participate in research because the healthcare team takes good care 
of me. 
  
4. The government sometimes exposes research participants to medicine 
and procedures known to be harmful to one’s health. 
  
5. Participating in research gives me a chance to “give back.”  
 
  
6. Research is part of a conspiracy to harm minority groups.  
 
  
7. I am willing to participate in research when I know exactly what I will be 
asked to do. 
  
8. I would not participate in research that does not benefit me because:   
8a. The study does not meet my medical or psychosocial needs. 
  
8b. The study involves randomization (i.e. there is a chance that I may 
not get the treatment). 
  
8c. The study could provide information about my health that I would 
rather not know about. 
  
8d. The study may cause me physical harm. 
 
  
9. Research studies will eventually lead to a cure or improved treatments 
for those who participate in them. 
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10. It makes me uncomfortable when my healthcare team wants to do  
research with me because:  
10a. The healthcare team will view me only as a “research participant” if I 
enroll. 
  
10b. The healthcare team will treat me differently, if I do not enroll.  
 
  
11. The hospital has researchers and community members review 
studies to make sure they are safe. 
  
12. Researchers sometimes undermine the power of God and God’s will. 
 
  
13. When the researcher is of the same race, I am more likely to 
participate. 
  
14. It is difficult to find time to participate in a research study because:  
14a. The study site is too far away. 
  
14b. I can’t take time off work. 
 
  
14c. I spend too much time at the hospital/clinic already. 
 
  
15. If my healthcare team is doing the research then I trust that it is good.   
16. Researchers sometimes hide information from participants prior to 
research. 
  
17. If researchers provided the following, it would lead to more 
participation in research:  
17a. Childcare 
  
17b. Money or gifts 
 
  
17c. Transportation costs 
 
  
17d. Telephone or internet participation 
 
  
18. Researchers often ask for financial information that may get back to 
the government and cause me to lose my check/benefits. 
  
19. Personal information given in research does not stay private and 
might hurt me or people I care about. 
  
20. Researchers are motivated by their own career goals and not the 
welfare of the people who participate in their studies. 
  
21. The following people would support my decision to participate in 
research:  
 21a. My healthcare team (doctor, nurse and social worker) 
  
21b. My family 
 
  
21c. My friends 
 
  
21d. My religious leader 
 
  
21e. My community agency 
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Research Participation Questionnaire - Caregiver   Participant ID #: ________ 
   
Directions: While the goal of going to the doctor or hospital is to get care that is meant to benefit 
the patient and his/her family, “research” asks patients and families to participate in certain 
activities in order to learn things that will hopefully help future patients and families.  
Please check AGREE or DISAGREE to reflect your agreement or disagreement with each of the 
following statements.  We are interested in YOUR opinion about medical (e.g., taking 
medication, blood samples drawn) and psychosocial (e.g., thoughts and feelings about illness, 
coping with illness) research studies; there are no right or wrong answers.  
 
 Agree Disagree 
1. We would participate in research that helps my child directly if:  
 1a. It gives us more contact with the healthcare team. 
  
1b. We learn more about my child’s illness. 
 
  
1c. We get tests/medicine and equipment that my child’s insurance won’t 
cover. 
  
1d. We get tests/medicine and equipment that are not available to the 
public. 
  
2. Research will cause my child discomfort in the following ways:  
2a. Require increased procedures. 
  
2b. Ask personal or upsetting questions.  
 
  
3. We participate in research because the healthcare team takes good 
care of my child. 
  
4. The government sometimes exposes research participants to medicine 
and procedures known to be harmful to one’s health. 
  
5. Participating in research gives my family and me a chance to “give 
back.” 
  
6. Research is part of a conspiracy to harm minority groups.  
 
  
7. We are willing to participate in research when we know exactly what 
we will be asked to do. 
  
8. We would not participate in research that does not benefit my child  
because:   
8a. The study does not meet my child’s medical or psychosocial needs. 
  
8b. The study involves randomization (i.e. there is a chance that my child 
would not get the treatment). 
  
8c. The study could provide information about my child’s health that I 
would rather not know about. 
  
8d. The study may cause my child physical harm. 
 
  
9. Research studies will eventually lead to a cure or improved treatments 
for those who participate in them. 
  
10. It makes me uncomfortable when my healthcare team wants to do  
research with my child because:  
10a. The healthcare team will view my child only as a “research 
participant” if I enroll. 
  
10b. The healthcare team will treat my child differently, if I do not enroll.  
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11. The hospital has researchers and community members review 
studies to make sure they are safe. 
  
12. Researchers sometimes undermine the power of God and God’s will. 
 
  
13. When the researcher is of the same race, I am more likely to 
participate. 
  
14. It is difficult to find time to participate in a research study because:  
14a. The study site is too far away. 
  
14b. I can’t take time off work. 
 
  
14c. We spend too much time at the hospital/clinic already. 
 
  
15. If my child’s healthcare team is doing the research then I trust that it is 
good. 
  
16. Researchers sometimes hide information from participants prior to 
research. 
  
17. If researchers provided the following, it would lead to more 
participation in research:  
17a. Childcare 
  
17b. Money or gifts 
 
  
17c. Transportation costs 
 
  
17d. Telephone or internet participation 
 
  
18. Researchers often ask for financial information that may get back to 
the government and cause me to lose my check/benefits. 
  
19. Personal information given in research does not stay private and 
might hurt me, my child, or people I care about. 
  
20. Researchers are motivated by their own career goals and not the 
welfare of the people who participate in their studies. 
  
21. The following people would support my decision to participate in 
research with my child:  
 21a. My child’s healthcare team (doctor, nurse and social worker) 
  
21b. Our family 
 
  
21c. Our friends 
 
  
21d. Our religious leader 
 
  
21e. Our community agency 
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Erikson Psychosocial Stage Inventory (EPSI)  Participant ID #: __________ 
Identity and Intimacy subscales 
 
Directions:  Please circle the number that corresponds to how true the following statements are 
for you. 
 Hardly 
ever 
true 
   Almost 
always 
true 
1. I get embarrassed when someone begins to tell me 
personal things 
1 2 3 4 5 
2. I change my opinion of myself a lot 1 2 3 4 5 
3. I'm ready to get involved with a special person 1 2 3 4 5 
4. I've got a clear idea of what I want to be 1 2 3 4 5 
5. I feel mixed up  1 2 3 4 5 
6. The important things in life are clear to me 1 2 3 4 5 
7. I've got it together 1 2 3 4 5 
8. I know what kind of person I am 1 2 3 4 5 
9. I'm warm and friendly 1 2 3 4 5 
10. I can't decide what I want to do with my life 1 2 3 4 5 
11. It's important to me to be completely open with my 
friends 
1 2 3 4 5 
12. I keep what I really think and feel to myself 1 2 3 4 5 
13. I have a strong sense of what it means to be 
female/male 
1 2 3 4 5 
14. I think it's crazy to get too involved with people 1 2 3 4 5 
15. I like myself and am proud of what I stand for 1 2 3 4 5 
16. I don't really know what l'm on about 1 2 3 4 5 
17. I care deeply for others 1 2 3 4 5 
18. I find I have to keep up a front when I'm with people 1 2 3 4 5 
19. I don't really feel involved 1 2 3 4 5 
20. I'm basically a loner 1 2 3 4 5 
21. I have a close physical and emotional relationship 
with another person 
1 2 3 4 5 
22. I prefer not to show too much of myself to others 1 2 3 4 5 
23. Being alone with other people makes me feel 
uncomfortable 
1 2 3 4 5 
24. I find it easy to make close friends 1 2 3 4 5 
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Original proposal Modification and rationale 
Recruitment 
Clinical care providers and research staff 
will distribute the Informational Fact 
Sheet and Permission to Contact Form to 
eligible participants during their clinical 
visits. 
Due to slow recruitment and feedback from clinical staff 
members who were assisting with recruitment that they were 
not remembering to distribute the study information; the 
study plan was modified such that these documents could be 
mailed to potentially eligible participants at home. 
Methods 
Informed consent/assent procedures Given the minimal risk nature of this study, a waiver of 
written documentation of informed consent/assent was 
requested and granted.  Verbal informed consent and assent 
was obtained from youth and parents as applicable. 
To evaluate understanding of informed 
consent, participants will complete an 
Evaluation to Sign Consent (ESC). 
All participants were administered and passed the ESC.  Due 
to word limitations imposed by the publishing journal, the 
final manuscript does not include a description of this 
process. 
Interviews will take place in a private 
conference room or office at the medical 
center at the convenience of the 
participant. 
In-person interviews also took place on the inpatient ward 
for patients with Cystic Fibrosis (and their parents) who were 
admitted for routine CF care.  Clinical providers and research 
staff from the CF clinic suggested this approach to relieve 
burden on these families.  Interviews also took place by 
phone for interested participants who could not travel to the 
Medical Center campus.  These modifications were made to 
promote participation when recruitment was very slow. 
Interview guide Revisions were made to the interview guide  to add probing 
questions to ask more directly about assent and research 
fatigue, and how participants were supported during past 
research participation. 
To triangulate interview data, the 
Decisional Conflict Scale (DCS) and 
PRPQ will be administered prior to the 
interview.   
The DCS and PRPQ were administered after the interview.  
This order was recommended in order to prevent obtaining 
bias responses to the qualitative interview.  
Participants to complete the Pediatric 
Research Participation Questionnaire 
(PRPQ) to capture motivators and barriers 
to participating in clinical research, but 
internal consistency not reported at the 
The PRPQ was not analyzed because data were incomplete 
due to a missing page and thus internal consistency could not 
be assessed.  Internal consistencies for the questionnaire 
were not reported elsewhere in the literature. 
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time of proposal defense.  Questionnaire 
to be administered but analyzed only if 
Cronbach’s alphas become available and 
are >0.7. 
NVivo software was to be used to prepare 
and analyze the interviews. 
Data analysis was conducted using hand coding due to the 
small sample size. 
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Background and Significance
• Clinical research has improved the care & treatment of 
youth with chronic health conditions (CHC)1-3
• Pediatric-focused agendas for HIV, cystic fibrosis (CF) and 
type 1 diabetes (T1D) research present many opportunities 
for participation4-7
• Important to understand factors impacting recruitment and 
retention:
• Burden of study requirements
• Research fatigue from repeat participation8-11
2
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Purpose
• This study explored whether youth with HIV, CF, and T1D 
and parents of youth with the same conditions describe 
features of research fatigue as factors that impact 
decision-making about research participation.
3
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Specific Aims
• Among youth with HIV, CF, and T1D, and parents of youth 
with the same conditions, to describe:
1. How communication and information impact   
decision-making about research
2. How participant’s values influence decision-making 
about research
3. What types of support are perceived to be important 
in order to minimize participation burden and research 
fatigue
4. Potential strategies to optimize support for decision-
making  and reduce research-related burden and 
fatigue
5
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Design, Sample and Setting
• Qualitative description14,15
• Purposive sampling
• Youth with HIV, CF & T1D and parents of youth with 
these CHCs who have made prior decisions about 
research participation
• Recruitment:
• Outpatient subspecialty clinics at an academic medical 
center where research activities are robust
• Assisted by clinical care providers & research staff
7
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Inclusion Criteria
8
Youth Parents
Diagnosed with HIV, CF, or T1D Parent or legal guardian of a youth 
with HIV, CF, or T1D
Age 13-21 Primary responsibility for providing 
consent for past study participation
Prior participation or invitation to 
participate in at least one study
Child with prior participation or
invitation to participate in at least one 
study
English speaking English speaking
Able to respond meaningfully to 
interview questions
Able to respond meaningfully to 
interview questions
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Procedures
• Study was approved by University IRB
• Recruitment:  May- December 2015
• Minimal-risk
• Waiver of written informed consent
• Informational “Fact Sheet” for consent and assent
• Retail gift card provided as gesture of gratitude
9
 
 
 

64 
 
 
 
Data analysis:  
Qualitative Content Analysis17
Read & 
summarize
Data 
reduction
CodingData 
rebuilding
Code links & 
categories/ 
themes
11
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Data analysis:  
Comparisons of interview responses & DCS 
Within-participant
• DCS will validate interview 
responses 
Across-participants
• Themes derived from 
those with high v. low DCS 
scores
12
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Ensuring Trustworthiness18
Credibility
• Triangulation
• Modified 
peer 
debriefing
• Member 
checks
Transferability
• Purposive 
sampling 
rich 
description
Dependability
• Audit trail
• Field notes
• Reflexive 
journaling
Confirmability
• Audit trail
• Triangulation
13
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Subject 
Demographics
15
n %
HIV 8 44
CF 5 28
T1D 5 28
Parents, N=8 Youth, N=10
M (range) M (range)
Age 48.75 (33-61) 18.5 (14-21)
Number of Past Studies
Invited to participate
Agreed to participate
Declined to participate
7.3 (1-20)
6.9 (1-20)
0.2 (0-1)
4.4 (1-12)
3.3 (1-6)
0.8 (0-6)
n (%) n (%)
Gender
Male
Female
0 (0)
8 (100)
6 (60)
4 (40)
Race
Caucasian
Other
7 (87.5)
1 (12.5)
8 (80)
2 (20)
Ethnicity
Non-Hispanic/Latino
Hispanic/Latino
Not reported
7 (87.5)
1 (12.5)
0 (0)
7 (70)
2 (20)
1 (10)
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Blurred Lines
• Blurred line between clinical care and research
• Clinicians serving in research roles
• Conveniences and challenges with this model
18
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Blurred Lines:  “A part of life.”
• Parent:  
“I guess I had so much else going on in life that 
participating in the study was kind of ‘behind the 
scenes.’  And I guess because we participated in 
a number of them, it just became routine as part 
of clinic...”
19
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Blurred Lines:  “A part of life.”
• Youth:
“My day consists of doing two, twenty-minute 
sessions on a percussion machine, inhalers, 
antibiotics…so it’s just a part of my life.  You can’t 
really get tired...I understand the necessity and 
when there’s an offer [to take part in research] 
being put out to me that could help, I’m gonna 
take it.”
20
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Blurred Lines:  Fundamental Trust
• Youth:
“I’ve known these people forever so if they didn’t 
have my best at heart then they wouldn’t be doing 
it.”
21
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Blurred Lines:  Fundamental Trust
• Parent:  
“We have the most contact with the nurse.  I think 
the person I feel most comfortable with is really 
who it should be…I wouldn’t say it should be a 
stranger.”
• Parent:  
“I feel so comfortable with her [social worker].  
That’s the only person that I trusted enough.”
22
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Blurred Lines: Informed Consent
• Parent:  
“I think it can be confusing at that moment 
because we are in clinic anyways and you don’t 
really have the time to sit and absorb what is 
actually happening and I think especially like with 
him, he was always a busy kid, so you were 
trying to rein him in and I mean, honestly, I 
probably didn’t even read three quarters of it, I 
just signed it.  When I knew that it wasn’t going to 
take more time than our normal clinic visits I was 
like ‘this has to be important’ and I signed it.”
23
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Blurred Lines: Informed Consent
• Youth: 
“I’ll do anything that they want me to do so long as 
it doesn’t have a major negative side.”
24
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Hope for the Future
• Hopeful and optimistic about the future
• Progress fosters hope and enthusiasm for additional 
research
• Cure, contributing to the greater good are factors that 
drive motivation to participate
• Transitions
25
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Hope for the Future:  “A two-way thing.”
26
• Youth:  
“Like when I was born, [I was] not expected to 
live more than a few years and that makes me 
really think…I have to repay her…[research is] 
to help the scientists and [the doctor] so it’s kind 
of a two way thing, it’s helping her, helping 
research and finding a cure one day.”
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Hope for the Future:  “A two-way thing.”
• Parent:  
“I always got that faith, you know that hope, that 
the more they study the more they learn and one 
day maybe they get the cure.  So that’s my 
motivation all the time.”
27
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Hope for the Future:  
“Think beyond ourselves.”
• Youth:  
“I'm never gonna say no unless it's like super high 
risk.  Because it's not only about me it's about a 
lot of other people.”
28
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Hope for the Future:  
“Think beyond ourselves.”
• Parent:  
“’I know it might bother you for that little bit of time 
while you are in there having those additional 
blood draws but…we kind of have to think beyond 
just ourselves for that short time…because a long 
time ago somebody else participated in a study 
for these medications you’re taking, you’ve had 
such a great outcome so whatever we can do to 
help somebody down the road is better.’”
29
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Hope for the Future:  Transitions
• Youth:  
“If I wanted to do it I would just say ‘I want to do 
it.’  They never really pushed me to do 
anything…it was all my decision even before I 
was 18.  They signed off but they would ask me 
if I wanted to do it and in the end, my decision 
was the final one.”
30
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Hope for the Future:  Transitions
• Parent:  
“[It will be important for her to have] someone to 
talk to about it.  I know she will come to me and 
ask to do it or not, if she should do it… I would 
be here to help her whenever she needed it.”  
31
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Both youth and parent scores on the 
Decisional Conflict Scale were low
32
Youth Parents
Scale M (range) M (range)
Total 10.3 (0-31) 12.1 (0-33)
Uncertainty
Informed
Values clarity
Support
Effective decision-making
9.8 (0-33)
10.6 (0-25)
14.4 (0-50)
8.3 (0-33)
8.5 (0-31)
9.4 (0-33)
12.5 (0-25)
18.9 (0-67)
10.4 (0-25)
10.1 (0-25)
Note.  Scores range from 0 [no decisional conflict; feels extremely 
certain/informed/clear about personal values/supported; good decision] to 100 
[extremely high decisional conflict; extremely uncertain/uninformed/unclear about 
personal values/unsupported; bad decision.]
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Limitations
• No participants who had only said no to a study
• Possible recall bias
• Sample was largely Caucasian and non-Hispanic/Latino
• Lack of diversity specific to HIV group
• Parents were all mothers/female guardians
34
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Implications
Fundamental Trust
• Awareness of competing 
interests of dual role
• Impact on Informed 
Consent
• Strategies:
• Simulation scenarios
• Input from Research Subject 
Advocates (RSA)
Transitions
• Supporting independent 
decision-making
• Research literacy skills as 
part of transition 
preparation
36
 
 
 
90 
 
 
 
Conclusions
• Integrated model of clinical care and research maximizes 
convenience  and alleviates research fatigue
• Pearl for supporting decision-making and promoting 
engagement of youth in research:
• Show gratitude by sharing study results/outcomes with 
participants whenever possible
37
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